LOUISVILLE, Ky.--(BUSINESS WIRE)--Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by GlaxoSmithKline for OJJAARA™ (momelotinib). OJJAARA is a kinase inhibitor indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia..

肯塔基州路易斯维尔（BUSINESS WIRE）-全国领先的独立专业药房Onco360®已被葛兰素史克（GlaxoSmithKline）选为OJJAARA的药房合作伙伴™ （莫莫替尼）。OJJAARA是一种激酶抑制剂，适用于治疗成人贫血的中度或高危骨髓纤维化（MF），包括原发性MF或继发性MF[真性红细胞增多症（PV）和原发性血小板增多症（ET）]。。

“Onco360 is grateful for the opportunity to partner with the team at GlaxoSmithKline and become a specialty pharmacy provider for OJJAARA,” said Benito Fernandez, Chief Commercial Officer. “We are proud to add this unique treatment option for adult MF patients with anemia.”

首席商务官贝尼托·费尔南德斯（Benito Fernandez）说：“Onco360感谢有机会与葛兰素史克（GlaxoSmithKline）的团队合作，成为OJJAARA的专业药房提供商。“我们很自豪为成人MF贫血患者添加这种独特的治疗选择。”

Based on the National Comprehensive Cancer Network (NCCN) guidelines for myeloproliferative neoplasms, MF is included with PV and ET within a group of heterogenous disorders of the hematopoietic system known as Philadelphia chromosome-negative myeloproliferative neoplasms (MPN). The estimated prevalence of MF in the United States is 13,000 patients.

根据国家综合癌症网络（NCCN）的骨髓增生性肿瘤指南，MF与PV和ET一起被纳入造血系统的一组异质性疾病，称为费城染色体阴性骨髓增生性肿瘤（MPN）。在美国，MF的估计患病率为13000名患者。

The median age at time of original primary MF diagnosis is 67 years old. Dependent upon genetic mutation status (i.e. CALR-mutant, JAK2-mutant, MPL-mutant, triple-negative MF) underlying the patient’s MF, median overall survival ranges from 3 to 18 years.1,2.

原始原发性MF诊断时的中位年龄为67岁。取决于患者MF的基因突变状态（即CALR突变体，JAK2突变体，MPL突变体，三阴性MF），中位总生存期为3至18岁。

The efficacy of OJJAARA in the treatment of adults with intermediate 1, intermediate 2, or high-risk MF, including primary MF, post-PV MF or post-ET MF, as defined by Dynamic International Prognostic Scoring System (DIPSS) or International Prognostic Scoring System (IPSS) for MF, was established in the MOMENTUM trial (NCT04173494) and in a subpopulation of adults with anemia in the SIMPLIFY-1 trial (NCT01969838).

根据动态国际预后评分系统（DIPSS）或国际预后评分系统（IPSS）的定义，OJJAARA治疗中度1，中度2或高危MF（包括原发性MF，PV后MF或ET后MF）MF，在MOMENTUM试验（NCT04173494）和SIMPLIFY-1试验（NCT01969838）中的成人贫血亚群中建立。

As part of the MOMENTUM trial, symptomatic and anemic MF patients treated with OJJAARA had a significantly improved incidence of Myelofibrosis Symptom Assessment Form (MFSAF) Version 4.0 Total Symptom Score Reduction of 50% or more (25% vs. 6%, p-value <0.01), a significantly improved incidence of transfusion independence (no transfusion or hemoglobin less than 8 g/dL between weeks 12 and 24; 30% vs.

作为MOMENTUM试验的一部分，用OJJAARA治疗的症状性和贫血性MF患者的骨髓纤维化症状评估表（MFSAF）4.0版总症状评分降低50%或更多（25%对6%，p值<0.01），输血独立发生率显着提高（第12周和第24周之间无输血或血红蛋白低于8 g/dL；30%vs。

20%, p-value 0.023), and a significantly improved incidence of spleen volume reduction by 25% or more (39% vs. 6%, p-value <0.0001) compared to symptomatic and anemic MF patients treated with Danazol.3.

20%，p值0.023），与用达那唑治疗的症状性和贫血性MF患者相比，脾脏体积减少的发生率显着提高25%或更多（39%对6%，p值<0.0001）。

Please see the full Prescribing Information for OJJAARA™.

请参阅OJJAARA的完整处方信息™.

About Onco360 Oncology Pharmacy:

关于Onco360肿瘤药房：

Onco360 is the nation’s largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers.

Onco360是全国最大的独立肿瘤药房和临床支持服务公司。Onco360成立于2003年，旨在汇集参与癌症治疗过程的利益相关者，满足肿瘤学家，患者，医院，癌症卓越中心，制造商，健康计划和付款人的专业需求。

It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States.

它通过URAC和ACHC认可的肿瘤药房网络在全国范围内分发。Onco360总部设在肯塔基州路易斯维尔，是PharMerica Corporation的旗舰专业制药品牌，PharMerica Corporation是美国领先的机构药房，专业输液和医院服务公司，为医疗机构提供服务。

For more information about Onco360, please visit Onco360.com..

有关Onco360的更多信息，请访问Onco360.com。。

References:

参考文献：

NCCN Guidelines Myeloproliferative Neoplasms Version 3.2022. Accessed September 2023.

NCCN指南骨髓增殖性肿瘤3.2022版。访问时间：2023年9月。

https://jnccn.org/view/journals/jnccn/20/9/article-p1033.xml

https://jnccn.org/view/journals/jnccn/20/9/article-p1033.xml

UpToDate® Clinical Manifestations and Diagnosis of Primary Myelofibrosis. Accessed September 2023.

UpToDate®临床表现和原发性骨髓纤维化的诊断。访问时间：2023年9月。

Clinical manifestations and diagnosis of primary myelofibrosis - UpToDate

原发性骨髓纤维化的临床表现和诊断-最新

OJJAARA Prescribing Information. Accessed September 2023.

OJJAARA处方信息。访问时间：2023年9月。

OJJAARA-PI-PIL.PDF (gskpro.com)

OJJAARA-PI-PIL.PDF（gskpro.com）

Trademarks:

商标：

GlaxoSmithKline, OJJAARA™ and associated logos are registered trademarks of the GSK group of companies.

葛兰素史克，OJJAARA™ 及相关徽标是葛兰素史克集团公司的注册商标。